T1	Premise 1258 1487	Based on the results of the area under the curve (AUC) analysis, patients receiving HMB/Arg/Gln had a strong trend higher LBM throughout the study as measured by both bioimpedance (p = 0.08) and skin-fold measurements (p = 0.08).
T2	Premise 1488 1613	Among the subset of patients receiving concurrent chemotherapy, there were again no significant differences in the endpoints.
T3	Claim 1694 1875	This trial was unable to adequately test the ability of beta-hydroxy beta-methylbutyrate, glutamine, and arginine to reverse or prevent lean body mass wasting among cancer patients.
R1	Support Arg1:T2 Arg2:T3	
T4	Premise 1614 1693	The secondary endpoints were also not significantly different between the arms.
R2	Support Arg1:T4 Arg2:T3	
